Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV prevention
Pharma
GSK to triple long-acting Apretude supply to boost global access
The long-acting HIV PrEP maker pledged at least 2 million doses for low-and middle-income countries in 2025 and 2026.
Zoey Becker
Oct 7, 2024 10:56am
Gilead aims to shake up HIV PrEP market with long-acting launch
Aug 9, 2024 11:42am
What 'The Next Berlin Patient' means for HIV drug development
Aug 2, 2024 9:43am
US appeals Gilead's trial win in Truvada, Descovy patent fight
Jul 9, 2024 11:00am
Gilead’s twice-yearly PrEP drug shows 100% efficacy
Jun 20, 2024 11:45am
Gilead enlists Raheem DeVaughn in HIV education, prevention work
Apr 12, 2024 7:10am
